Effects of Inhibition of Nitric Oxide Synthase on Muscular Arteries During Exercise: Nitric Oxide Does Not Contribute to Vasodilation During Exercise or in Recovery

Kevin O’Gallagher, MBBS; Husain Shabeeh, PhD; Shahzad Munir, MD; Ali Roomi, MBBS; Benyu Jiang, PhD; Antoine Guilcher, PhD; Sally Brett, PhD; Philip Chowienczyk, PhD

BACKGROUND: Basal release of nitric oxide (NO) from the vascular endothelium regulates the tone of muscular arteries and resistance vasculature. Effects of NO on muscular arteries could be particularly important during exercise when shear stress may stimulate increased NO synthesis.

METHODS AND RESULTS: We investigated acute effects of NO synthase inhibition on exercise hemodynamics using N\textsuperscript{G}-monomethyl-l-arginine (l-NMMA), a nonselective NO synthase inhibitor. Healthy volunteers (n=10, 5 female, 19–33 years) participated in a 2-phase randomized crossover study, receiving l-NMMA (6 mg/kg, iv over 5 minutes) or placebo before bicycle exercise (25–150 W for 12 minutes). Blood pressure, cardiac output (measured by dilution of soluble and inert tracers) and femoral artery diameter were measured before, during, and after exercise. At rest, l-NMMA reduced heart rate (by 16.2±4.3 bpm relative to placebo, \(P<0.01\)), increased peripheral vascular resistance (by 7.0±1.4 mmHg per L/min, \(P<0.001\)), mean arterial blood pressure (by 8.9±3.5 mmHg, \(P<0.05\)), and blunted an increase in femoral artery diameter that occurred immediately before exercise (change in diameter: 0.14±0.04 versus 0.32±0.06 mm after l-NMMA and placebo, \(P<0.01\)). During/after exercise l-NMMA had no significant effect on peripheral resistance, cardiac output, or on femoral artery diameter.

CONCLUSIONS: These results suggest that NO plays little role in modulating muscular artery function during exercise but that it may mediate changes in muscular artery tone immediately before exercise.

Key Words: exercise physiology ■ nitric oxide ■ nitric oxide synthase

Nitric oxide (NO) synthesized by nitric oxide synthase (NOS) within the vascular endothelium is known to regulate the tone of resistance and muscular arteries.\(^1\),\(^2\) A transient increase in shear stress caused by increase in blood flow is a powerful stimulus to release of NO and dilation of muscular arteries (“flow-mediated dilatation”).\(^3\) Sustained increases in flow also cause dilation of muscular arteries but such dilation is largely NO-independent.\(^4\) Exercise causes dilation of muscular arteries supplying the exercising limb. This has important effects on systemic hemodynamics in that it reduces pressure wave reflection, reducing pressure augmentation in systole and hence load on the left ventricle.\(^5\),\(^6\) The contribution of NO to such exercise-induced vasodilation during which there is both a sustained increase in flow and an increase in flow pulsatility is unknown.

The purpose of the present study was to determine effects of NOS inhibition on muscular artery function during exercise using the nonselective inhibitor N\textsuperscript{G}-monomethyl-l-arginine (l-NMMA). The direct effects of l-NMMA on muscular arteries supplying skeletal
muscle were assessed using high-resolution ultrasound of the femoral artery before and immediately after leg exercise. In addition, a secondary objective was to confirm results of previous studies on effects of L-NMMA on cardiac output (CO) and total peripheral resistance during exercise using pulmonary uptake of inert and soluble gas tracers.

METHODS
The data that support the findings of this study are available from the corresponding author upon reasonable request.
systolic shoulder of the radial waveform using inbuilt software in the SphygmoCor system. During exercise, finger blood pressure was measured using a servo-controlled finger cuff (Finometer; Finapres medical systems, the Netherlands). The SphygmoCor system cannot be used during exercise and the Finometer was therefore used to obtain recordings of the digital artery waveform from which peripheral AI was estimated as previously described.6 Briefly, the late systolic shoulder of the digital waveform was determined by first identifying local minima and maxima of the first derivative of the pressure signal (to identify consecutive changes in the gradient of the waveform) and then defined by the intersection of tangents to the curve at these points. This algorithm was applied to individual waveforms with a mean value of peripheral AI calculated from ≥10 individual waveforms. Values of peripheral AI identified by the algorithm were marked on the waveform and were verified by inspection of the waveform. We have previously shown that radial and digital artery waveforms obtained from the SphygmoCor and Finometer waveforms are similar8 and that values of peripheral AI obtained from Finometer traces are comparable to those obtained using the SphygmoCor system.6

**Cardiac Output**
CO was determined by pulmonary uptake of soluble and inert gas tracers (InnoCor; Innovision, Scandinavia). Subjects re-breathed a gas mixture (1% SF₆, 5% N₂O, and 94% O₂) for 20-s periods. Expired gases were sampled continuously and analyzed by an infrared photoacoustic analyzer.5 Stroke volume was calculated from CO and heart rate. Systemic vascular resistance was calculated from mean arterial blood pressure (MAP) and CO and expressed in units of mmHg per L/min.

**Femoral Artery Diameter**
High-resolution ultrasound (Acoustic, Aspen with 7 MHz linear probe) was used to image the femoral artery proximal to the artery bifurcation. Femoral artery diameter was measured in diastole using wall tracking software (Medical Imaging Applications, LCC, IA).

**Statistical Analysis**
Data were assessed for normality using the Shapiro–Wilk test. Changes from baseline during infusion of placebo were assessed by analysis of variance for repeated measures. When this showed an overall change, values at individual time points were compared by Student paired t test. Changes in variables after l-NMMA compared with placebo were assessed by 2-way ANOVA using baseline values before l-NMMA/placebo as the reference. All tests were 2-sided and P<0.05 was taken as significant. Data are presented as mean±SEM.

**Table 1. Hemodynamic Measurements at Rest, During Exercise, and in Recovery After Infusion of Placebo/l-NMMA**

| Variable   | Drug     | Baseline  | Postinfusion | 75 W | 125 W | 15 min | 30 min |
|------------|----------|-----------|--------------|------|-------|--------|--------|
| HR, bpm    | Placebo  | 67.2±6.2  | 66.9±7.0     | 116.8±8.0  | 146.5±7.0 | 76.5±6.8 | 69.5±6.6 |
| l-NMMA     | 65.6±5.7 | 49.1±2.8†| 107.7±6.6†  | 140.9±8.2† | 67.9±6.1 | 69.3±6.1 |
| SBP, mmHg  | Placebo  | 117.4±6.2 | 126.9±7.5    | 153.2±9.4  | 166.3±8.0 | 117.9±5.7 | 128.1±7.7 |
| l-NMMA     | 120.2±4.6 | 138.3±4.5†| 152.1±8.2  | 168.1±5.3  | 127.4±4.3 | 131.6±4.7 |
| DBP, mmHg  | Placebo  | 69.2±4.7  | 74.9±4.8     | 95.3±8.8   | 101.0±6.2 | 73.1±4.9  | 79.1±7.4  |
| l-NMMA     | 68.9±3.6 | 81.9±4.4  | 89.0±4.3†   | 99.7±4.1†  | 74.1±3.1  | 79.1±2.6  |
| MAP, mmHg  | Placebo  | 83.4±5.0  | 90.6±5.2     | 113.6±8.8 | 122.7±6.8 | 87.3±5.0  | 94.5±7.8  |
| l-NMMA     | 85.1±3.8 | 101.2±4.3†| 110.4±4.9†  | 122.7±4.6 | 90.7±3.3  | 95.1±3.0  |
| CO, L/min  | Placebo  | 5.1±0.4   | 5.1±0.4     | 10.6±0.5   | 13.0±0.5 | 5.2±0.3   | 4.6±0.3   |
| l-NMMA     | 5.3±0.4 | 4.3±0.4†  | 9.9±0.5     | 12.2±0.7   | 5.7±0.5   | 5.0±0.4   |
| Stroke vol, mL | Placebo | 79.2±5.1 | 81.0±6.8 | 93.8±5.9 | 99.3±3.3 | 73.4±7.2 | 71.8±6.7 |
| l-NMMA     | 85.6±9.4 | 86.8±3.9 | 94.0±5.0 | 101.8±7.6 | 82.5±6.2 | 77.0±6.6 |
| PVR, mmHg per L/min | Placebo | 16.8±1.4 | 18.1±1.1 | 10.6±0.6 | 9.2±0.4 | 17.2±1.4 | 21.0±1.8 |
| l-NMMA     | 16.4±0.7 | 24.7±1.7‡ | 11.3±0.6 | 9.9±0.7   | 17.6±1.3 | 19.5±1.3  |
| AI, %      | Placebo  | 53.3±5.5  | 44.2±5.2     | 44.3±7.2   | 28.6±3.1 | 36.0±4.4 | 42.9±6.3 |
| l-NMMA     | 50.2±4.5 | 70.2±6.5† | 51.0±4.3 | 33.5±6.4† | 49.5±5.3† | 48.2±4.0* |

AI indicates peripheral systolic augmentation index measured from the radial artery; CO, cardiac output; DBP, diastolic blood pressure; HR, heart rate; l-NMMA, L- monomethyl-l-arginine; MAP, mean arterial blood pressure; PVR, peripheral vascular resistance; and SBP, systolic blood pressure.

*P<0.05 compared with baseline.
†P<0.05 compared with placebo.
‡P<0.05 for change from baseline compared with placebo. N=10.
RESULTS

Hemodynamic measurements at rest before infusion of \(L\)-NMMA/placebo, after infusion of \(L\)-NMMA/placebo immediately before exercise, during exercise, and during recovery are summarized in Table 1. Individual patient data for femoral artery diameter, peripheral AI, and peripheral vascular resistance can be seen in Figure S1.

Effects of \(L\)-NMMA at Rest Before Exercise

During infusion of placebo before exercise there was no significant change in heart rate, but there was a significant increase in blood pressure, MAP increasing from 83.4±5.0 to 90.6±5.2 mmHg \((P<0.05)\). Relative to placebo, \(L\)-NMMA produced a decrease in heart rate \((-16.4±3.4 \text{ versus } -0.2±1.8 \text{ bpm after } L\)-NMMA and placebo, respectively, \(P<0.01)\) and an increase in peripheral resistance \((8.3±1.4 \text{ versus } 1.3±1.1 \text{ mmHg per L/min after } L\)-NMMA and placebo, respectively, \(P<0.001)\). There was no significant change in stroke volume, but the reduction in heart rate produced a tendency for CO to decrease after \(L\)-NMMA. Despite this, MAP also increased after \(L\)-NMMA relative to placebo \((16.1±3.1 \text{ versus } 7.2±2.2 \text{ mmHg after } L\)-NMMA and placebo, respectively, \(P<0.05)\).

Despite the increase in MAP during infusion of placebo immediately before exercise, AI decreased from 53.3±5.5 to 44.2±5.2\% \((P<0.05)\), accompanied by an increase in femoral artery diameter of 0.32±0.06 mm \((\text{Table 2}, P<0.001)\). \(L\)-NMMA blunted the dilation of the femoral artery \((\text{change in diameter } 0.14±0.04 \text{ versus } 0.32±0.06 \text{ mm after } L\)-NMMA and placebo, respectively, \(P<0.01, \text{Figure})\) and reversed the decrease in peripheral AI, with an increase in peripheral AI relative to that seen during infusion of placebo. This was still significant \((\text{increase of } 16.8±4.3\% \text{ relative to placebo, } P<0.01)\) when corrected for change in heart rate, assuming a change in peripheral AI of 4\% to 5\% per 10 bpm change in heart rate as previously described.\(^6,10\)

Table 2. Femoral Artery Diameter at Baseline and in Recovery After Placebo/\(L\)-NMMA

|                      | Placebo       | \(L\)-NMMA    |
|----------------------|---------------|---------------|
| Diameter (mm)        | Change (mm)   | Diameter (mm) | Change (mm)   |
| Baseline             | 7.95±0.33     | 8.11±0.26     |
| Postinfusion         | 8.27±0.35\*   | 0.32±0.06     |
| 5 min postexercise   | 8.21±0.37\*   | 0.37±0.12     |
| 10 min postexercise  | 8.45±0.33\*   | 0.50±0.11     |
| 15 min postexercise  | 8.40±0.34\*   | 0.45±0.12     |

\(l\)-NMMA indicates N\(^\text{G}\)-monomethyl-L-arginine.

\(*P<0.02 \text{ compared with baseline.}  \\
\(\dagger P<0.05 \text{ compared with placebo.}  \\
\(\ddagger P<0.05 \text{ vs placebo.}  \\
\)$
longer significant. Dilation of the femoral artery after placebo immediately before the start of exercise was maintained in the immediate recovery period up to 15 minutes (Table 2). By contrast to the dilation of the femoral artery occurring immediately before exercise, the sustained dilation of the femoral artery seen in the recovery period was not blunted by l-NMMA: The mean difference between the dilatation of the femoral artery (relative to baseline) in the recovery period between placebo and l-NMMA was −0.03 mm [−0.15, 0.08] (mean [95% CI]). The upper 95% CI is thus small in comparison to changes observed at rest.

**DISCUSSION**

This study provides insights into several aspects of the role of NOS in the physiological response to exercise in humans. The key finding is that the regulation of muscular artery tone during physiological exercise appears to be NOS-independent.

**Effect of NOS Inhibition on Muscular Arteries**

Increased flow and hence shear stress in muscular arteries is a powerful stimulus to an increase in arterial caliber. The flow-mediated dilatation response to a transient increase in flow is mediated almost exclusively by NO. However, the response to a more sustained increase in flow is largely NO-independent. This current study represents the first data on the effects of a sustained physiological increase in flow through muscular arteries supplying exercising skeletal muscle. Leg exercise was associated with dilatation of the femoral artery immediately before and after exercise. However, although l-NMMA blunted dilatation of the femoral artery immediately before initiation of exercise, l-NMMA was without effect on femoral artery diameter immediately after exercise. These data are therefore consistent with NOS-independent mechanisms of muscular artery dilatation in response to a sustained increase in blood flow.

**Effect of NOS Inhibition on Cardiovascular Hemodynamic Properties**

Previous studies examining effects of acute inhibition of NOS at rest using l-NMMA have demonstrated a marked increase in peripheral resistance and modest increase in blood pressure. In the present study, measurements after infusion of l-NMMA/placebo were made immediately before initiation of exercise and therefore may have been influenced by central command. Nevertheless, effects of l-NMMA on peripheral resistance and blood pressure before initiation of exercise were as predicted from studies at rest: l-NMMA produced a marked increase of 40% in peripheral resistance compared with placebo. Despite this increase in peripheral resistance, there was only a modest increase in MAP of 9 mmHg after l-NMMA compared with placebo. Pressor effects of l-NMMA were opposed by a reduction in CO explained by a reduction in heart rate rather than in stroke volume, which remained unchanged. Reduction in heart rate could be explained by a reflex bradycardia but is also consistent with NO regulation of sinoatrial node activity.

During exercise the vasodilatation of resistance vasculature supplying exercising skeletal muscle is thought to be determined by numerous “metabolic,” endothelium-derived, and other mediators with likely redundancy of individual mediators. The contribution of NO to exercise-induced vasodilatation of resistance vasculature is relatively minor. Thus, NOS inhibition might be expected to have little influence on the decrease in peripheral vascular resistance during exercise. In the present study, despite producing a marked increase in peripheral resistance immediately before exercise, l-NMMA had no significant effect on CO, MAP, or peripheral resistance during exercise, a finding in agreement with a previous study in which peripheral resistance was estimated from bioimpedance measurements of CO.

**Effect of NOS Inhibition on Peripheral AI**

AI is a complex index, influenced by ventricular–vascular interactions but may be reduced as result of a dilation of muscular arteries and reduced pressure wave reflection. l-NMMA did not significantly block the decrease in peripheral AI during exercise and, although the decrease in peripheral AI in recovery was blunted by l-NMMA, this was explained by a concomitant reduction in heart rate. Thus, both direct measurements of arterial diameter and measures of pressure augmentation suggest that NOS inhibition has little effect on tone of muscular arteries during exercise.

**Effect of NOS Inhibition Immediately Before Exercise**

A surprising finding was that after infusion of placebo alone, there was a reduction in peripheral AI and dilation of the femoral artery immediately before exercise. These changes are likely to represent a neurally mediated response in anticipation of exercise similar to that known to exist in resistance vasculature but for which the mechanism is unknown (and which have been documented in epicardial coronary arteries). l-NMMA blunted this dilation of the femoral artery immediately before exercise and reversed the reduction in AI by an amount that could not be explained by the change in heart rate. The present study was not designed to test the complex feed-forward regulation of tone by central command, but these findings would be consistent with blockade, by l-NMMA, of neurally induced vasodilatation of muscular arteries immediately before exercise.
CONCLUSIONS
This study suggests that in healthy subjects, inhibition of NOS is without effect on heart rate, stroke volume, or peripheral resistance during exercise. NOS inhibition appears to blunt dilation of muscular arteries supplying exercising muscle immediately before exercise but does not inhibit dilation of these arteries during or after exercise. Further studies are required to determine the influence of NO on neurally mediated changes in arterial tone in anticipation of exercise and to the NO-independent mechanism maintaining dilation of muscular arteries during exercise.

ARTICLE INFORMATION
Received August 7, 2019; accepted January 24, 2020.

Affiliations
From the Cardiovascular Division, Department of Clinical Pharmacology, King’s College London School of Medicine, St Thomas’ Hospital, London, United Kingdom.

Sources of Funding
This work was supported by the British Heart Foundation. Dr O’Gallagher is supported by the UK Medical Research Council (Clinical Research Training Fellowship MR/R017751/1). The authors acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London.

REFERENCES
1. Kinlay S, Creager MA, Fukumoto M, Hikita H, Fang JC, Selwyn AP, Ganz P. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension. 2001;38:1049–1053.
2. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation. 2002;105:213–217.
3. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuliez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314–1319.
4. Mullen MJ, Kharbanda RK, Cross J, Donald AE, Taylor M, Wallace P, Deanfield JE, MacAllister RJ. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res. 2001;88:145–151.
5. Munir S, Guilcher A, Kamalesh T, Clapp B, Redwood S, Marber M, Chowienczyk P. Peripheral augmentation index defines the relationship between central and peripheral pulse pressure. Hypertension. 2008;51:112–118.
6. Munir S, Jiang B, Guilcher A, Brett S, Redwood S, Marber M, Chowienczyk P. Exercise reduces arterial pressure augmentation through vasodilatation of muscular arteries in humans. Am J Physiol Heart Circ Physiol. 2008;294:H1654–H1656.
7. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens. 1993;11:1375–1380.
8. Milasseau SC, Guigui FG, Kelly RP, Prasad K, Cockcroft JR, Ritter JM, Chowienczyk PJ. Noninvasive assessment of the digital volume pulse. Comparison with the peripheral pressure pulse. Hypertension. 2000;36:962–966.
9. Clemensen P, Christensen P, Norsk P, Gronlund J. Modified photo- and magnetoacoustic multigas analyzer applied in gas exchange measurements. J Appl Physiol (1985). 1994;76:2832–2839.
10. Wilkinson IB, Mohammad NH, Tyrrell S, Hall IR, Webb DJ, Paul VE, Levy T, Cockcroft JR. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens. 2002;15:24–30.
11. Brett SE, Cockcroft JR, Mant TG, Ritter JM, Chowienczyk PJ. Haemodynamic effects of inhibition of nitric oxide synthase and of L-arginine at rest and during exercise. J Hypertens. 1998;16:429–435.
12. Haynes WG, Hand MF, Dockrell ME, Eadington DW, Lee MR, Hussein Z, Benjamini N, Webb DJ. Physiological role of nitric oxide in regulation of renal function in humans. Am J Physiol. 1997;272:F364–F371.
13. Chowdhary S, Harrington D, Bonser RS, Coote JH, Townsend JN. Chronotropic effects of nitric oxide in the denervated human heart. J Physiol. 2002;541:645–651.
14. Clifford PS, Hellsten Y. Vasodilatory mechanisms in contracting skeletal muscle. J Appl Physiol (1985). 1985;97:393–403.
15. Modi BN, Rahman H, Arri S, Ellis H, Williams R, Assress K, Clapp B, Redwood S, Perera D. Resting coronary flow varies with normal cardiac catheter laboratory stimuli. Cardiovasc Revasc Med. 2019;20:669–673.
16. Furline ES, Harmon MF, PAith JE, Garvey EP. Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine. Biochemistry. 1993;32:8512–8517.
17. Furline ES, Harmon MF, PAith JE, Knowles RG, Saiter M, Kiff RJ, Duffy C, Hazelwood R, Oplinger JA, Garvey EP. Selective and potent inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide synthase by S-methyl-L-thiocitruline and S-ethyl-L-thiocitruline. J Biol Chem. 1994;269:26672–26683.
18. Steedon M, Melikian N, Dvorakowski R, Shabeek H, Jiang B, Byrne J, Casadei B, Chowienczyk P, Shah AM. Effects of neuronal nitric oxide synthase on human coronary artery diameter and blood flow in vivo. Circulation. 2009;119:2666–2662.

Disclosures
None.

Supplementary Material
Figure S1

Limitations
Key limitations of this study include the small sample size, which restricts analysis of variation in response because of subject demographics and other characteristics and also the inability to measure femoral arterial diameter in real-time during exercise, instead relying on postexercise measures. An additional limitation is the nonselective nature of NOS-inhibition induced by L-NMMA, which inhibits neuronal NOS (nNOS) in addition to endothelial NOS. In the epicardial coronary arteries (a conduit arterial bed), it has been demonstrated that endothelial NOS and nNOS have distinct roles in the regulation of local arterial tone (ie, nNOS regulates basal arterial tone, whereas endothelial NOS is responsible for substance-P stimulated vasodilatation). The use of a nonselective NOS-inhibitor in this study therefore does not provide any insight into any nNOS-dependent mechanisms in the regulation of conduit arterial tone. Further work could include assessing the differential effects of L-NMMA compared with S-methyl-L-thiocitrulline, an nNOS-selective inhibitor. This would shed further light on whether the femoral arterial dilatation noted just before exercise is indeed because of nNOS-mediated signaling, as part of neurally mediated feed-forward mechanisms.
Figure S1. Haemodynamic and Femoral arterial measurements at rest and in recovery after infusion of placebo/L-NMMA.

A: Femoral arterial diameter (placebo), B: Femoral arterial diameter (L-NMMA), C: Peripheral systolic augmentation index (AI, placebo), D: Peripheral systolic augmentation index (L-NMMA), E Peripheral vascular resistance (PVR, placebo), F: Peripheral vascular resistance (L-NMMA).